Stock NIPH EI- NILE CO. FOR PHARMACEUTICALS AND CHEMICAL INDUSTRIES
Add to a list
To use this feature you must be a member
Log inSign up

Financials EI- Nile Co. for Pharmaceuticals and Chemical Industries

Equities

NIPH

EGS38331C012

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
72.91 EGP -.--% Intraday chart for EI- Nile Co. for Pharmaceuticals and Chemical Industries -8.86% -12.26%
Feb. 15 The Nile Co. for Pharmaceuticals and Chemical Industries Reports Earnings Results for the Half Year Ended December 31, 2023 CI
2023 The Nile Co. for Pharmaceuticals and Chemical Industries Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 142.9 191.8 308.5 354.1 359 404.9
Enterprise Value (EV) 1 182.7 188.9 264.3 287.9 385.2 596
P/E ratio -8.12 x 28.6 x - 5.5 x 4 x 3.4 x
Yield - - - 5.72% 8.38% 12.5%
Capitalization / Revenue 0.31 x 0.3 x 0.38 x 0.47 x 0.41 x 0.4 x
EV / Revenue 0.4 x 0.3 x 0.33 x 0.38 x 0.44 x 0.59 x
EV / EBITDA 28.5 x 5.33 x 2.02 x 2.67 x 2.76 x 3.39 x
EV / FCF -5.36 x 2.4 x 21 x 5.53 x -6.04 x -4.67 x
FCF Yield -18.7% 41.6% 4.76% 18.1% -16.6% -21.4%
Price to Book 0.53 x 0.77 x - 0.95 x 0.83 x 0.85 x
Nbr of stocks (in thousands) 10,125 10,125 10,125 10,125 10,125 10,125
Reference price 2 14.11 18.94 30.47 34.97 35.46 39.99
Announcement Date 9/4/18 9/9/19 9/14/21 9/14/21 9/19/22 9/20/23
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 459.9 638.3 812.5 755.5 876.8 1,005
EBITDA 1 6.408 35.45 131.1 107.7 139.4 175.9
EBIT 1 -6.416 23.24 116.4 95.6 125.4 162.8
Operating Margin -1.39% 3.64% 14.32% 12.65% 14.31% 16.19%
Earnings before Tax (EBT) 1 -16.56 8.542 104.5 82.6 116.3 145.4
Net income 1 -17.59 6.696 93.38 64.42 89.67 119.2
Net margin -3.82% 1.05% 11.49% 8.53% 10.23% 11.86%
EPS 2 -1.737 0.6613 - 6.363 8.856 11.77
Free Cash Flow 1 -34.08 78.61 12.57 52.04 -63.81 -127.7
FCF margin -7.41% 12.32% 1.55% 6.89% -7.28% -12.7%
FCF Conversion (EBITDA) - 221.76% 9.59% 48.33% - -
FCF Conversion (Net income) - 1,174.11% 13.46% 80.79% - -
Dividend per Share - - - 2.000 2.970 5.000
Announcement Date 9/4/18 9/9/19 9/14/21 9/14/21 9/19/22 9/20/23
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 39.9 - - - 26.2 191
Net Cash position 1 - 2.89 44.2 66.2 - -
Leverage (Debt/EBITDA) 6.224 x - - - 0.1881 x 1.086 x
Free Cash Flow 1 -34.1 78.6 12.6 52 -63.8 -128
ROE (net income / shareholders' equity) -6.16% 3.21% 31.9% 18.2% 22.4% 26.2%
ROA (Net income/ Total Assets) -0.68% 2.43% 11.6% 8.54% 10.5% 11.3%
Assets 1 2,600 275 805.3 754.8 851.8 1,059
Book Value Per Share 2 26.70 24.40 - 36.70 42.60 47.30
Cash Flow per Share 2 4.570 7.660 - 10.80 5.290 2.120
Capex 1 6.38 1.69 5.14 4.38 48.7 27.6
Capex / Sales 1.39% 0.26% 0.63% 0.58% 5.56% 2.75%
Announcement Date 9/4/18 9/9/19 9/14/21 9/14/21 9/19/22 9/20/23
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
EI- NILE CO. FOR PHARMACEUTICALS AND CHEMICAL INDUSTRIES Stock EI- Nile Co. for Pharmaceuticals and Chemical Industries
-12.26% 15.45M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 235B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. NIPH Stock
  4. Financials EI- Nile Co. for Pharmaceuticals and Chemical Industries